logo

Mallinckrodt Plc (MNK)



Trade MNK now with
  Date
  Headline
10/1/2019 6:47:28 AM Mallinckrodt Says Positive Top-Line Findings From Observational Registry To Assess Treatment Response To Acthar Gel
9/23/2019 6:47:06 AM Mallinckrodt Announces Positive Top-line Results From Pivotal Phase 3 Clinical Trial Of StrataGraft® Regenerative Tissue
9/13/2019 6:49:16 AM Mallinckrodt:Acthar Gel May Be Cost-Effective Option Vs Other Late-Line, Adult Treatments For Multiple Sclerosis Relapse
9/10/2019 6:46:31 AM Mallinckrodt Agrees To Sell BioVectra Inc. To H.I.G. Capital For $250 Mln
8/15/2019 6:46:29 AM Mallinckrodt Reports Positive Top-Line Results From Pivotal Phase 3 CONFIRM Trial Of Terlipressin
8/12/2019 6:58:27 AM Mallinckrodt Confirms Enrollment Of First Patient In Phase 2a Study Of MNK-6106 In Hepatic Cirrhosis And Chronic HE
8/6/2019 6:10:50 AM Mallinckrodt Q2 Adj. EPS $2.53 Vs. $2.16 Prior Year
7/18/2019 6:56:57 AM Mallinckrodt, Silence Therapeutics Collaborate To Develop, Commercialize RNAi Therapeutics
7/18/2019 6:55:57 AM Mallinckrodt Agrees To Make An Equity Investment Of $5 Mln In Silence Therapeutics
6/24/2019 6:56:38 AM Mallinckrodt Achieves 50% Enrollment For Phase 2B Trial Investigating The Use Of Acthar Gel In ALS
6/13/2019 6:49:34 AM Mallinckrodt Says Phase 4 Multicenter Study Assessing Efficacy And Safety Of Acthar® Gel Meets Primary Measures
  
 
>